Better Health for All

Veru Inc. develops and commercializes medicines for men's and women's health, including FDA-approved products like FC2 Female Condom for STI/pregnancy prevention and ENTADFI for benign prostatic hyperplasia.

Its pipeline includes enobosarm for obesity and breast cancer, and sabizabulin for COVID-19, influenza, and atherosclerotic cardiovascular disease. All these products are intended to provide substantial health benefits, with no evidence of significant negative health impacts from its core offerings. The company's R&D expenses increased from $12.8 million in fiscal 2024 to $15.6 million in fiscal 2025, representing 10.4% of its $150 million estimated annual revenue, indicating significant investment in health innovation. However, the company's risk disclosures are general, and specific details on adverse event rates for its products are not provided, making it difficult to assess the safety record quantitatively. The company's products are subject to governmental pricing controls in many foreign markets, and it faces risks in obtaining insurance reimbursement, suggesting potential accessibility challenges. Veru has an agreement with Afaxys Group Services to offer FC2 Female Condom through a GPO, aiming to provide preferred pricing and access for up to 31 million women and men in community and public health centers. During the COVID-19 pandemic, Veru developed sabizabulin, which showed a 51.6% relative reduction in deaths in a Phase 3 trial, but the FDA declined Emergency Use Authorization. The company's patent for enobosarm polymorph composition of matter expires in 2029 (potentially 2034 with PTE), and for sabizabulin molecule composition of matter in 2031 (potentially 2036 with PTE), indicating a standard approach to patent protection.

Fair Money & Economic Opportunity

Veru Inc. is a biopharmaceutical company focused on developing and commercializing medicines, not a financial institution.

The ethical value 'Fair Money & Economic Opportunity' assesses companies that lend, insure, move, or store money. As Veru Inc. does not offer consumer financial services or products, all Key Performance Indicators (KPIs) under this value are not applicable. The company's activities, such as increasing research and development expenses to $15.6 million in fiscal 2025 from $12.8 million in fiscal 2024, represent standard business reinvestment in its core pharmaceutical operations, not community finance initiatives. Information regarding clinical trials for specific patient demographics (e.g., older patients, those with obesity) relates to health services, not financial inclusion. Similarly, the availability of investor-related data (e.g., SEC filings, earnings webcasts) does not pertain to customer finance data portability or control.

Honest & Fair Business

Veru Inc. expanded its board of directors from 6 to 7 members, with Loren Mark Katzovitz appointed as a new independent director.

This means approximately 14.28% (1 out of 7) of the board members are explicitly stated as independent. The company has an anti-corruption policy that explicitly prohibits improper payments, bribes, kickbacks, excessive commissions, inappropriate gifts, and entertainment to customers, suppliers, and government officials, with specific mention of Foreign Corrupt Practices Act (FCPA) compliance. This policy was adopted on October 31, 2016, and includes a commitment to rigorous enforcement with disciplinary action and possible discharge for violations.

Kind to Animals

Veru Inc. is actively conducting animal trials for its novel enobosarm formulation and chronic nonclinical toxicology animal studies for sabizabulin, as requested by the FDA.

This indicates that no products are certified cruelty-free, leading to a -100 for cruelty_free_cert_share. The company's reliance on animal studies, with no evidence of employing non-animal testing methods, results in a -100 for alt_testing_usage. The company's policy permits animal testing, particularly when mandated by the FDA, which aligns with a -50 for animal_testing_policy. The company uses 10,000-15,000 animals annually for testing, mapping to a -60 for animal_testing_volume.

No War, No Weapons

The provided articles for Veru Inc. (VERU.US) do not contain any information relevant to the 'No War, No Weapons' ethical value.

, focusing on the company's R&D, also explicitly states it contains no data relevant to arms or defense contracts, peacebuilding, or conflict. , an SEC filing summary, indicates no data was available for analysis. Therefore, no KPIs related to this value can be scored based on the evidence provided.

Planet-Friendly Business

The provided articles explicitly state that sustainability data is currently unavailable for Veru Inc.

No specific quantitative data, regulatory actions, certifications, or other relevant metrics related to planet-friendly business practices could be extracted from the sources. Therefore, it is not possible to assess the company against the defined KPIs in the rubric.

Safe & Smart Tech

Veru Inc. has not identified any material cybersecurity incidents that have affected its operations, business strategy, results, or financial condition.

The company requires employees to undergo security awareness training when hired and conducts periodic phishing tests. It has implemented access controls, firewalls, intrusion detection and prevention systems, and vulnerability and patch management processes. The company's board of directors oversees cybersecurity risk, with the Chief Financial Officer primarily responsible for managing these risks, assisted by a third-party service provider. The company's privacy notice, last updated November 7, 2022, outlines rights for individuals in the European Economic Area and California residents to access, correct, delete, and restrict processing of their personal information. California residents can opt-out of personal information sales, with requests acted upon within 15 days and reauthorization requests waiting at least 12 months. However, the company limits California consumers to two data access or portability requests within a 12-month period. The company states compliance with HIPAA, CMIA, CCPA, FCRA, GLBA, and GDPR.

Zero Waste & Sustainable Products

The provided articles do not contain specific, quantifiable data points for any of the Key Performance Indicators related to Zero Waste & Sustainable Products.

Information regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is not available in the provided evidence.